Metabolic Bone Diseases and New Drug Developments
Authors:
Open Access
- 28 March 2022
- journal article
- review article
- Published by The Korean Society of Applied Pharmacology in Biomolecules & Therapeutics
- Vol. 30 (4) , 309-319
Abstract
Vijayakumar Natesan and Sung-Jin Kim. Biomolecules & Therapeutics 2022;30:309-19. https://doi.org/10.4062/biomolther.2022.007Keywords
This publication has 102 references indexed in Scilit:
- Clinical Use and Mechanisms of Infliximab Treatment on Inflammatory Bowel Disease: A Recent UpdateBioMed Research International, 2013
- Belimumab: First targeted biological treatment for systemic lupus erythematosusJournal of Pharmacology and Pharmacotherapeutics, 2011
- Bone Health and the Female Athlete Triad in Adolescent AthletesThe Physician and Sportsmedicine, 2011
- DenosumabDrugs & Aging, 2011
- Diagnosis and management of osteoporosis in the older seniorClinical Interventions in Aging, 2009
- Coeliac disease. From A – ZExpert Opinion on Therapeutic Patents, 2007
- Metabolic Bone Disease in ChildrenTreatments in Endocrinology, 2006
- Sustained Osteomalacia of Long Bones Despite Major Improvement in Other Hypophosphatasia-Related Mineral Deficits in Tissue Nonspecific Alkaline Phosphatase/Nucleotide Pyrophosphatase Phosphodiesterase 1 Double-Deficient MiceThe American Journal of Pathology, 2005
- TrastuzumabDrugs, 2002
- Hormonal Determinants and Disorders of Peak Bone Mass in ChildrenThe Journal of Clinical Endocrinology & Metabolism, 2000